The portfolio maintains a sizable cost advantage over competitors, priced within the cheapest fee quintile among peers.
VanEck Pharmaceutical ETF PPH
Morningstar’s Analysis PPH
Will PPH outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 63.8
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Eli Lilly and Co | 13.01 | 93.1 Mil | Healthcare |
Novo Nordisk AS ADR | 8.23 | 58.9 Mil | Healthcare |
Johnson & Johnson | 6.55 | 46.9 Mil | Healthcare |
AbbVie Inc | 6.25 | 44.8 Mil | Healthcare |
Bristol-Myers Squibb Co | 5.12 | 36.6 Mil | Healthcare |
Merck & Co Inc | 5.11 | 36.6 Mil | Healthcare |
Novartis AG ADR | 5.10 | 36.5 Mil | Healthcare |
AstraZeneca PLC ADR | 5.08 | 36.4 Mil | Healthcare |
Zoetis Inc Class A | 4.69 | 33.5 Mil | Healthcare |
Haleon PLC ADR | 4.67 | 33.5 Mil | Healthcare |